



Luxembourg, 20 December 2024

## Environmental and Social Completion Sheet (ESCS)

### Overview

Project Name:	RENAL TREATMENT (EGFF)
Project Number:	2018-0623
Country:	France
Project Description:	The project supports the Promoter's research and development investments to progress a pipeline of pediatric-friendly therapeutics that address critical unmet medical needs in the field of rare and orphan diseases across the pharmaceutical value-chain.

### Summary of Environmental and Social Assessment at Completion

**EIB notes the following Environmental and Social performance and key outcomes at Project Completion.**

The project mainly covered investments in RDI that were carried out in the Promoter's existing facilities or other research centres already authorised

The promoter's R&D facilities and practices are in compliance with relevant national and EU regulations and the promoter maintains adequate internal procedures and management practices. The use of animal testing is minimised and in line with the EU Directive 2010/63/EU. In addition, The Company has adequate policies and procedures in place to outsource and manage clinical trials in the different regions of the world in accordance with the EU 536/2014 regulation. The clinical trials which are sponsored by the project are performed under regulated and strictly controlled conditions, in existing specialised facilities which are regularly inspected by competent authorities - EMA in Europe and/or national equivalent bodies in the rest of the world (e.g. FDA).

*No significant environmental or social issues were noted.*

#### Summary opinion of Environmental and Social aspects at completion:

EIB is of the opinion based on reports from the promoter, site visits by the EIB team that the Project has been implemented in line with EIB Environmental and Social Standards, applicable at the time of appraisal.